Tag: Everest Medicines Limited
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines...
Everest Medicines (HKG: 1952) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s...
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global...
Everest Medicines (HKG: 1952) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent...
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List...
Everest Medicines (HKG 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...
